Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
15.03.2023 - Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash PositionHOUSTON, March 15, 2023 (GLOBE NEWSWIRE) - Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company ...